{"entity":{"id":"leeds-cancer-centre","kind":"institution","name":"Leeds Cancer Centre, St James's University Hospital","aka":["Leeds Teaching Hospitals NHS Trust","Bexley Wing","Leeds Institute of Medical Research"],"tldr":"One of the largest cancer centres in the UK, known for colorectal cancer pathology and trials, melanoma research, myeloma and MR-guided radiotherapy.","summary":"The Leeds Cancer Centre at St James's University Hospital is among the UK's largest single-site cancer centres, serving Yorkshire with radiotherapy, surgery, haematology and paediatric oncology. University of Leeds research includes Philip Quirke's pathology work that established circumferential resection margin assessment in rectal cancer, the Leeds Clinical Trials Research Unit that ran FOxTROT (neoadjuvant chemotherapy in colon cancer) and UK myeloma trials, and melanoma epidemiology and genetics. Leeds was an early UK adopter of the Elekta Unity MR-linac and hosts the Leeds Institute of Medical Research at St James's and a CRUK Centre. The centre also has a national profile in teenage and young adult cancer and in health data research.","asOf":"2026-09-09","links":[{"label":"Leeds Cancer Centre","url":"https://www.leedsth.nhs.uk/services/leeds-cancer-centre/"}],"tags":[],"related":[],"cancers":["colorectal","melanoma","multiple-myeloma","dlbcl","pancreatic","rectal-cancer","nsclc","lung-cancer","skin-cancer","basal-cell-carcinoma"],"sections":["radiation","surgery"],"technologies":["mr-linac","imrt-igrt","histopathology-ihc"],"targets":[],"drugs":[],"companies":["elekta"],"institutions":["cruk"],"pathways":[],"terms":["neoadjuvant-adjuvant"],"trials":["cr07","foxtrot","star-trec","ylst"],"people":["brendan-brown","david-sebag-montefiore","matt-seymour","matthew-callister"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Leeds","country":"GB","lat":53.807,"lng":-1.52,"institutionType":"hospital","website":"https://www.leedsth.nhs.uk/services/leeds-cancer-centre/","university":"University of Leeds","programs":["Colorectal cancer pathology and trials","MR-linac radiotherapy","Myeloma trials","Melanoma epidemiology","Clinical Trials Research Unit"]},"route":"/institutions/leeds-cancer-centre/","neighbours":{"cancer":[{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"section":[{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"},{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/"}],"technology":[{"id":"histopathology-ihc","kind":"technology","name":"Histopathology & immunohistochemistry","route":"/technologies/histopathology-ihc/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"mr-linac","kind":"technology","name":"MR-guided adaptive radiotherapy","route":"/technologies/mr-linac/"}],"company":[{"id":"elekta","kind":"company","name":"Elekta","route":"/companies/elekta/"}],"institution":[{"id":"ammf","kind":"institution","name":"AMMF, the Cholangiocarcinoma Charity","route":"/institutions/ammf/"},{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"},{"id":"birmingham-cancer-centre","kind":"institution","name":"University Hospitals Birmingham / University of Birmingham Cancer Research Centre","route":"/institutions/birmingham-cancer-centre/"},{"id":"west-yorkshire-harrogate-cancer-alliance","kind":"institution","name":"West Yorkshire and Harrogate Cancer Alliance","route":"/institutions/west-yorkshire-harrogate-cancer-alliance/"}],"term":[{"id":"neoadjuvant-adjuvant","kind":"term","name":"Neoadjuvant / adjuvant / perioperative","route":"/terms/neoadjuvant-adjuvant/"}],"trial":[{"id":"europac","kind":"trial","name":"EUROPAC","route":"/trials/europac/"},{"id":"foxtrot","kind":"trial","name":"FOxTROT","route":"/trials/foxtrot/"},{"id":"cr07","kind":"trial","name":"MRC CR07","route":"/trials/cr07/"},{"id":"safir-abc10","kind":"trial","name":"SAFIR-ABC10","route":"/trials/safir-abc10/"},{"id":"star-trec","kind":"trial","name":"STAR-TREC","route":"/trials/star-trec/"},{"id":"ylst","kind":"trial","name":"YLST","route":"/trials/ylst/"}],"person":[{"id":"brendan-brown","kind":"person","name":"Brendan Brown","route":"/people/brendan-brown/"},{"id":"david-sebag-montefiore","kind":"person","name":"David Sebag-Montefiore","route":"/people/david-sebag-montefiore/"},{"id":"matt-seymour","kind":"person","name":"Matt Seymour","route":"/people/matt-seymour/"},{"id":"matthew-callister","kind":"person","name":"Matthew Callister","route":"/people/matthew-callister/"},{"id":"peter-hillmen","kind":"person","name":"Peter Hillmen","route":"/people/peter-hillmen/"}],"paper":[{"id":"paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016","kind":"paper","name":"HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials","route":"/key-papers/paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016/"},{"id":"paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014","kind":"paper","name":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies","route":"/key-papers/paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014/"}],"collection":[{"id":"uk-hpb-specialist-centres","kind":"collection","name":"UK specialist HPB cancer centres","route":"/collections/uk-hpb-specialist-centres/"}]}}